Date: June 12, 2026

Regulatory Disclosure Summary

Nature of Regulatory Action

  • The United States Food and Drug Administration (US FDA) inspected the Eugia Unit-III formulation manufacturing facility.
  • The facility is owned and operated by Eugia Pharma Specialities Ltd., a wholly owned subsidiary of Aurobindo Pharma Limited.
  • The facility is located at Phase-III, TSIIC, EPIP, IDA, Pashamylaram, Patancheru Revenue Mandal, Sangareddy District, 502307, Telangana, India.
  • The inspection period was from January 27, 2026, to February 06, 2026.
  • The inspection concluded with 11 observations.

Official Classification and Date

  • On June 12, 2026, the company received communication from the US FDA.
  • The FDA has determined the inspection classification for this facility to be \"Official Action Indicated\" (OAI).

Impact Assessment

  • The company explicitly states: \"There is no impact on the Company's financials or operations due to the said action.\"

Company Statement and Forward Outlook

  • The company states it is \"committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.\"
  • The company commits to keeping the stock exchanges informed of any further developments relating to this matter.